Researchers Discover Test to Predict Which Patients with Rare Blood Disease Will Respond to Only FDA-Approved Treatment, and Identify Alternative Therapy

New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.